Payment overview · 2025
General Payments
$894.47
48 reported records · 15 companies
Healthcare provider profile · identity verified
John Poole Forney, MD
Allopathic & Osteopathic Physicians|Family Medicine · MILLERSBURG, PA · NPI 1437314895
Verified facts
What the public records show
CMS Open Payments records show John Poole Forney, MD received $894.47 in general payments during 2025 across 48 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 593 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $388.33 | 43.4% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.61 | 10.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.93 | 9.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.20 | 5.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.25 | 5.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.01 | 4.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.94 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.97 | 3.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.66 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.59 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.85 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.65 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.62 | 1.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.72 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $849.47 | 47 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $372.84 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.93 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $66.70 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.77 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.66 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 593 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 253 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
593 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1352 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 1089 | 140 |
| Lisinopril | Lisinopril | 1029 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 912 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 694 | 69 |
| Furosemide | Furosemide | 663 | 58 |
| Eliquis | Apixaban | 593 | 39 |
| Gabapentin | Gabapentin | 553 | 44 |
| Metformin Hcl | Metformin Hcl | 540 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 498 | 50 |
| Sertraline Hcl | Sertraline Hcl | 483 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 444 | 61 |
| Simvastatin | Simvastatin | 399 | 47 |
| Losartan Potassium | Losartan Potassium | 393 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 365 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 335 | 28 |
| Buspirone Hcl | Buspirone Hcl | 334 | 16 |
| Famotidine | Famotidine | 306 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 25 |
| Potassium Chloride | Potassium Chloride | 262 | 23 |
| Donepezil Hcl | Donepezil Hcl | 255 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 28 |
| Jardiance | Empagliflozin | 253 | 23 |
| Memantine Hcl | Memantine Hcl | 210 | suppressed |
| Baclofen | Baclofen | 208 | 27 |
| Bumetanide | Bumetanide | 202 | 16 |
| Meloxicam | Meloxicam | 183 | 45 |
| Trazodone Hcl | Trazodone Hcl | 180 | 20 |
| Risperidone | Risperidone | 179 | suppressed |
| Carvedilol | Carvedilol | 164 | 18 |
| Divalproex Sodium | Divalproex Sodium | 159 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 147 | 14 |
| Prednisone | Prednisone | 146 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 145 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 141 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 136 | suppressed |
| Lamotrigine | Lamotrigine | 135 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 121 | 23 |
| Glimepiride | Glimepiride | 120 | 33 |
| Allopurinol | Allopurinol | 112 | 12 |
| Omeprazole | Omeprazole | 111 | 35 |
| Trulicity | Dulaglutide | 111 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 106 | suppressed |
| Myrbetriq | Mirabegron | 103 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 101 | 16 |
| Lorazepam | Lorazepam | 99 | 20 |
| Olanzapine | Olanzapine | 95 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 91 | 26 |
| Mirtazapine | Mirtazapine | 91 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 89 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 89 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 85 | suppressed |
| Atenolol | Atenolol | 83 | suppressed |
| Haloperidol | Haloperidol | 79 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 21 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 65 | suppressed |
| Nifedipine Er | Nifedipine | 64 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 62 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 48 |
| Glipizide | Glipizide | 57 | 13 |
| Kerendia | Finerenone | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | 14 |
| Enalapril Maleate | Enalapril Maleate | 55 | suppressed |
| Lovastatin | Lovastatin | 55 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 54 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Pentoxifylline | Pentoxifylline | 52 | suppressed |
| Perphenazine | Perphenazine | 52 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 50 | suppressed |
| Klor-Con 8 | Potassium Chloride | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 35 |
| Amoxicillin | Amoxicillin | 46 | 36 |
| Benztropine Mesylate | Benztropine Mesylate | 46 | suppressed |
| Carbamazepine | Carbamazepine | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Azithromycin | Azithromycin | 36 | 30 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Cephalexin | Cephalexin | 29 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 18 |
| Ramipril | Ramipril | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 20 |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | 11 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Lactulose | Lactulose | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Torsemide | Torsemide | 21 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 19 | 17 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Entacapone | Entacapone | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 16 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $894.47 · 48 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | BREZTRI, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, RELISTOR, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRULANCE, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error